Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Interest & Investment Income readings, the most recent being $2.4 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 13.47% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 31.69% decrease, with the full-year FY2025 number at $9.4 million, down 36.07% from a year prior.
  • Interest & Investment Income hit $2.4 million in Q4 2025 for Enanta Pharmaceuticals, up from $2.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $4.7 million in Q3 2023 to a low of $255000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 5 years was $2.3 million (2025), compared with a mean of $2.3 million.
  • Biggest five-year swings in Interest & Investment Income: soared 883.72% in 2023 and later tumbled 39.83% in 2025.
  • Enanta Pharmaceuticals' Interest & Investment Income stood at $258000.0 in 2021, then soared by 284.88% to $993000.0 in 2022, then surged by 332.83% to $4.3 million in 2023, then crashed by 34.88% to $2.8 million in 2024, then dropped by 13.47% to $2.4 million in 2025.
  • The last three reported values for Interest & Investment Income were $2.4 million (Q4 2025), $2.1 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.